Flagship Pioneering has picked London as the site of the venture capital powerhouse’s first company-creation unit outside of ...
Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to ...
Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.
While Kyverna awaits an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy, the biotech ...
Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its ...
Charles River Laboratories has acquired two of Tigermed’s Frontage laboratory sites in Pennsylvania for $470 million upfront ...
The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post ...
AstraZeneca has acquired vaccine bioconjugation specialist Omn | AstraZeneca has acquired vaccine bioconjugation specialist ...
Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...
Vor Bio is paying RemeGen $10 million upfront in cash and issuing warrants valued at approximately $46 million for rights to RC298 outside Greater China, adding a long-acting drug ...
The U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will ...
Bristol Myers Squibb is merging its research and development divisions under the leadership of Cristian Massacesi, M.D.